Biotechnology

Filter

Current filters:

None

Popular Filters

27 to 51 of 2324 results

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

11-09-2014

Clinical stage oncology drug development company MabVax Therapeutics has entered agreements with Memorial…

BiotechnologyCancer therapeuticsChimeric antigen receptorMabVax TherapeuticsOncologyResearchUSA

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

ReproCELL acquires the iPS Cell Business unit of Stemgent

10-09-2014

Japan-based ReproCELL is to acquire the iPS Cell Business unit of Privately-held US firm Stemgent. This…

BiotechnologyMergers & AcquisitionsReproCELLStemgent

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

Value of patents as enabling and supporting medical research stressed by AusBiotech

09-09-2014

Patents are at the core of enabling genetic tests, treatments, vaccines and cures resulting from medical…

AustraliaBiotechnologyPatentsResearch

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

Hyperion terminates DaiPep277 program due to "misconduct"

08-09-2014

Shares of Hyperion Therapeutics’ plunged 11% to $24.61 in pre-market trading today, after the company…

Andromeda BiotechAndromeda GalaxyAstronomyBiotechnologyDiabetesDiaPep277HyperionHyperion TherapeuticsResearchUSA

Eisai divests US Zonegran rights to Concordia

Eisai divests US Zonegran rights to Concordia

07-09-2014

Japanese drugmaker Eisai (TYO: 4523) says its US subsidiary has entered into an agreement to divest its…

BiotechnologyConcordia PharmaceuticalsEisaiMergers & AcquisitionsNeurologicalUSAZonegran

Novel vaccine cuts recurrence in HER2 positive breast cancer patients

Novel vaccine cuts recurrence in HER2 positive breast cancer patients

07-09-2014

A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy…

BiotechnologyGalena BioPharmaOncologyResearch

Soligenix acquires Ph III-ready oncology clinical program

Soligenix acquires Ph III-ready oncology clinical program

05-09-2014

US clinical-stage biopharma firm Soligenix has acquired a novel orphan drug candidate, known as SGX301…

BiotechnologyhypericinMergers & AcquisitionsOncologySGX301Soligenix

FDA lifts partial clinical hold on OncoMed's ipafricept

05-09-2014

Shares of US biotech companies OncoMed Pharmaceuticals rose 5.6% to $17.68 on news that the US Food and…

BayerBiotechnologyipafriceptOncologyOncoMed PharmaceuticalsRegulationResearchUSA

Australia's federal court rules that companies can patent genetic material

Australia's federal court rules that companies can patent genetic material

05-09-2014

The Full Bench of the Federal Court of Australia has decided a private company may hold a patent on a…

AustraliaBiotechnologyIntellectual propertyLegalPatentsPharmaceutical sciencesRegulation

Action urged to capitalize on opportunity as Australian budget tables reveal loss of support

04-09-2014

The release of the Australian federal government’s ‘Science, Research and Innovation Budget Tables’…

AustraliaBiotechnologyFinancialResearch

AbbVie links with Calico in up to $1.5 billion effort on drug discovery

AbbVie links with Calico in up to $1.5 billion effort on drug discovery

04-09-2014

US pharma company AbbVie has entered a novel R&D collaboration with recently-formed Calico, intended…

AbbVieBiotechnologycalicoNeurologicalOncologyResearch

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

Strong Ph IIb results with Dezima’s CETP inhibitor TA-8995 in dyslipidemia

Strong Ph IIb results with Dezima’s CETP inhibitor TA-8995 in dyslipidemia

03-09-2014

Privately-held Dutch biotech firm Dezima Pharma says it has received very positive results in its Phase…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaMitsubishi TanabeResearchTA-8995

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

03-09-2014

US biotech firm ACADIA Pharmaceuticals says that the US Food and Drug Administration has granted Breakthrough…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNuplazidpimavanserinRegulationUSA

27 to 51 of 2324 results

Back to top